Heart failure & cardiomyopathies
Contemporary heart failure evidence in 2025: a joint summary of key trials from the European Journal of Heart Failure and ESC Heart Failure Journal
Authors' conclusion
Despite an expanding therapeutic armamentarium, delayed diagnosis, underuse of evidence-based therapies, and organizational barriers continue to limit clinical impact.
Study context
- Population
- Patients with heart failure (HF) across the EF spectrum
- Outcome
- Contemporary HF evidence (epidemiology, aetiology, diagnostics, treatment)
Methodological detailsnarrative summary of key trials from European Journal of Heart Failure and ESC Heart Failure Journal
- Narrative summary of key trials from European Journal of Heart Failure and ESC Heart Failure Journal
Main finding
As reported in the abstract
- Multi-parametric biomarkers, advanced imaging and AI-based tools enable earlier diagnosis, refined risk stratification and personalized management
- Aetiology-specific insights (hypertensive and ischaemic heart disease, cardiomyopathies, amyloidosis, pregnancy-related HF) are reshaping clinical pathways
- Expanding evidence for SGLT2 inhibitors and MRAs across the EF spectrum; early and intensive GDMT initiation strategies
- Persistent gaps between trial evidence and real-world implementation
Original publication
Contemporary heart failure evidence in 2025: a joint summary of key trials from the European Journal of Heart Failure and ESC Heart Failure Journal. Eur J Heart Fail. Published 17 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →